Eli Lilly

News

Lilly bags FDA okay for Wegovy pill rival orforglipron

Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

News

Novo hits back at rivals with cut-price Wegovy subscriptions

Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.

News

Eli Lilly makes $7.8bn takeover play for Centessa

Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.

News

Lilly puts up to $2.75bn into Insilico alliance

Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.

Market Access

A panel on direct-to-patient at Reuters Pharma USA

In DTC's watershed moment, trust and partnership are key

More and more pharma companies are turning to direct-to-patient access models. But the consensus at Reuters Pharma USA is that they can't do it alone.

News

Novo unveils first data for 'triple G' agonist in diabetes

Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.

Lilly bags FDA okay for Wegovy pill rival orforglipron

Novo hits back at rivals with cut-price Wegovy subscriptions

Eli Lilly makes $7.8bn takeover play for Centessa

Lilly puts up to $2.75bn into Insilico alliance

In DTC's watershed moment, trust and partnership are key

Novo unveils first data for 'triple G' agonist in diabetes

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks